Life Sciences

  • October 23, 2026

    Taxation With Representation: Milbank, De Brauw, Wachtell

    In this week's Taxation With Representation, EQT Private Equity announces a takeover offer for life sciences testing company Qiagen NV, Salesforce acquires customer engagement platform Braze and London Stock Exchange Group buys U.S. credit intelligence provider Octus.

  • October 23, 2026

    US Opens Duty Investigations Into Chinese Compounds

    The U.S. Department of Commerce is opening investigations into whether certain chemical compounds imported from China are being sold at less than fair value and are subsidized, the department said Friday.

  • October 22, 2026

    Nestle's Solgar Has Dangerous Vitamin B6 Levels, Suit Says

    Nestle was hit with a proposed false advertising class action Wednesday in New Jersey federal court alleging its Solgar VM-75 supplements contain dangerous levels of vitamin B6, which can heighten the risk of developing peripheral neuropathy or worsen the condition.

  • October 22, 2026

    DEA Judge Will Not Reopen Marijuana Rescheduling Hearing

    The coalition fighting marijuana legalization won a partial victory after a Drug Enforcement Administration's administrative law judge on Thursday allowed into the record a U.S. Government Accountability Office report the group championed but denied new testimony on it, saying the report "speaks for itself."

  • October 22, 2026

    Gilead Reaches $45M Settlement To End Kickback Claims

    The Texas Office of the Attorney General on Thursday announced that pharmaceutical company Gilead Sciences Inc. signed off on a $45 million settlement to end claims that the company ran an illegal kickback scheme in order to get prescribers to favor its medications.

  • October 22, 2026

    Elsevier Beats Defamation Suit Over Air Purifier Article

    An indoor air quality company failed to prove academic publisher Elsevier acted with malice in printing an article questioning the effectiveness of its air purification technology sufficient to sustain a claim for defamation, a North Carolina federal judge ruled Thursday.

  • October 22, 2026

    Full 9th Circ. Won't Review Surgical Robot Antitrust Fight

    The full Ninth Circuit declined to reconsider an appellate panel's recent decision reviving a surgical repair company's antitrust suit alleging Intuitive Surgical blocked third parties from supplying parts for its popular da Vinci surgery robot, according to an order issued Thursday.

  • October 22, 2026

    J&J Says Justices' Denial Backs Tossing Fee Suit At 3rd Circ.

    Johnson & Johnson told the Third Circuit Thursday that the U.S. Supreme Court's recent decision not to take up a group of executives' federal benefits dispute backed its position in an appeal from J&J workers who alleged their health plans were saddled with excessive prescription drug fees.

  • October 22, 2026

    Mylan Settles Connecticut's EpiPen Price Claims For $8M

    Mylan Pharmaceuticals has struck another deal to resolve claims that it illegally inflated prices for EpiPens, this time settling Connecticut state enforcers' allegations of antitrust and consumer protection law violations for $8 million.

  • October 22, 2026

    Purdue Trusts Say Sackler Bid Again Destabilizes Ch. 11 Plan

    The Purdue Pharma bankruptcy trust and trustees for some members of the Sackler family have filed separate documents in a New York bankruptcy court challenging moves they described as continued attempts by Richard S. Sackler and his wife, Lin Gao, to block parts of the drugmaker's bankruptcy plan.

  • October 22, 2026

    10x Genomics Ends Patent Fight Against Parse In Delaware

    10x Genomics has told a Delaware federal judge it will no longer pursue a patent case against Parse Biosciences Inc. over methods of analyzing genetic information, a move following the Federal Circuit's refusal to revive the remaining three patents-at-issue.

  • October 22, 2026

    FTC Wants More Info On Curium's $8B Deal For Lantheus

    The Federal Trade Commission has requested additional information about Curium's planned $8 billion acquisition of fellow radiopharmaceutical company Lantheus Holdings Inc., extending a waiting period that prevents the transaction from closing.

  • October 22, 2026

    Imperative Gets PTAB To Trim Inari Medical Device Claims

    The Patent Trial and Appeal Board has invalidated claims in an Inari Medical Inc. patent on valves used in surgery to prevent blood loss, handing another win to challenger Imperative Care as it fends off an infringement lawsuit in California.

  • October 22, 2026

    DLA Piper Hires Shook Hardy Product Liability Partner

    DLA Piper has hired a former Shook Hardy & Bacon LLP product liability partner in San Francisco who has decades of experience defending companies in high-stakes disputes involving hundreds of millions of dollars.

  • October 21, 2026

    7 Firms Advise EQT, Qiagen On $12.1B Take-Private Deal

    A long list of firms — including Davis Polk & Wardwell LLP, Linklaters LLP and Milbank LLP — are steering Sweden-based EQT Private Equity's $12.1 billion takeover of life sciences testing company Qiagen NV, according to a Wednesday announcement.

  • October 21, 2026

    Reckitt Benckiser Denies Firing Manager For Whistleblowing

    Reckitt Benckiser urged a New Jersey federal judge to end a former senior regulatory manager's suit alleging she was fired for raising product safety issues, arguing Tuesday she rejected a lateral transfer amid a global reorganization and unsuccessfully gambled the company would give in to her promotion and higher pay demands.

  • October 21, 2026

    Ill. Judge Questions Bid To Block 340B Drug Discount Law

    An Illinois federal judge seemed hesitant Wednesday to halt a state law barring drugmakers from trying to impose restrictions on pharmacies under contract with a federal drug pricing discount program, saying the state seems to be maximizing public health in an area the statute doesn't address.

  • October 21, 2026

    Intuitive Surgical Strikes $450M Deal In Robot Antitrust Suit

    Intuitive Surgical said in its quarterly earnings report Tuesday that it reached a $450 million settlement to resolve a hospital class action alleging it monopolized the market for servicing its da Vinci surgical robots, subject to approval by a California federal judge.

  • October 21, 2026

    Amarin Ends 'Skinny Label' Patent Case Against Hikma

    Amarin Pharma Inc. is dropping its patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, months after the U.S. Supreme Court shut the case down.

  • October 21, 2026

    Squire Patton Lands Akerman's Public Finance Co-Leader

    Squire Patton Boggs LLP announced Wednesday that it has added the co-chair of Akerman LLP's public finance group to bolster its capacity to handle public finance, healthcare finance and other matters.

  • October 21, 2026

    High Court Lets Block On Prison Gender Care Ban Stand

    The U.S. Supreme Court on Wednesday allowed federal prisons to continue to offer gender transition medical services to incarcerated people.

  • October 20, 2026

    Medical Device Co. Beats Investors' Alleged Demand Drop Suit

    A New York federal judge has dismissed a proposed shareholder class action alleging medical device maker Integer Holdings Corp. hid plummeting demand for cardiac devices and misled investors about its overall growth, concluding that the allegations do not suggest its disclosures in 2024 and 2025 were untrue or deceptive.

  • October 20, 2026

    Squires Grants 10 Patent Review Bids, Rejects 2 Others

    In his latest round of decisions, U.S. Patent and Trademark Office Director John Squires has granted 10 petitions seeking review of patents and denied two others, both on discretionary grounds.

  • October 20, 2026

    Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy

    Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of their prescription allergy drug Xolair amounts to patent infringement.

  • October 20, 2026

    Zymergen Investors Win Final OK Of $125M IPO Deal

    Investors in the now-defunct biotechnology company Zymergen received final approval of their $125 million deal ending claims that the company misled shareholders ahead of its initial public offering, while plaintiffs' attorneys also had their fee request approved. 

Expert Analysis

  • Beware Daubert Pitfalls With Technical Experts In Patent Suits

    Recent decisions on Daubert motions in patent cases show that courts will exclude expert testimony that lacks a solid factual or methodological foundation, regardless of the expert's credentials — underscoring the importance of demonstrating reliability, say attorneys at Steptoe.

  • 4 Tips On Expert Gatekeeping From J&J Talc Deal

    Author Photo

    Johnson & Johnson's successful campaign to exclude plaintiff-side oncologist testimony about whether its talcum powder caused ovarian cancer, which prompted the recent resolution of 70,000 claims, offers lessons on how product liability defendants can reshape risk calculation by rigorously applying expert admissibility rules, say attorneys at Hollingsworth.

  • Series

    Playing Bid Whist Makes Me A Better Lawyer

    Author Photo

    As a child, I viewed bid whist as a family tradition and a source of friendly card game competition, but as a lawyer, I see it as a tool that has helped me cultivate skills like communication, teamwork, risk assessment and composure, says Keyonn Pope at Riley Safer.

  • Teva, Wyeth Show How Claimed Advances Shape Enablement

    Author Photo

    Two recent Federal Circuit decisions involving method-of-treatment claims — Teva v. Eli Lilly and Wyeth v. AstraZeneca — reached opposite enablement outcomes from strikingly similar procedural postures, but a closer comparison of the cases reveals a three-step framework for understanding the court's reasoning, says Kendall Gurule at Polsinelli.

  • Opinion

    Calif. Bill Goes Too Far In Trying To Regulate Attorney AI Use

    Author Photo

    California’s first-in-the-nation act regulating how attorneys and arbitrators use generative artificial intelligence will likely soon become law, but read broadly, the provisions may dissuade lawyers from employing AI at all, thereby depriving them of key work tools, says Joshua Wurtzel at Schlam Stone.

  • AI Rise In Healthcare Demands New Cybersecurity Strategies

    Author Photo

    As artificial intelligence-related capabilities are increasingly integrated into medical devices and healthcare operations, organizations must adapt their compliance playbook to address evolving cybersecurity needs and implement lifecycle-based risk assessment approaches, say attorneys at Covington.

  • Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks

    Author Photo

    Regulators' complaint against telehealth company Hims & Hers alleging deceptive practices serves as a reminder that the privacy principles developed under consumer protection laws and predating omnibus statutes remain in force, and sensitive data governance continues to be a crucial component of compliance, say attorneys at Venable.

  • How Cannabis Rescheduling Is Reshaping Bankruptcy

    Author Photo

    As broader cannabis rescheduling awaits a recommended decision, cannabis companies continue to test the boundaries of the Bankruptcy Code, with the recent Cannabist Chapter 15 recognition order suggesting that governmental resistance may be reduced in future filings, say attorneys at Thompson Coburn.

  • Opinion

    New CMS Medical Device Pathway May Have Limited Effect

    Author Photo

    The Centers for Medicare & Medicaid Services' new pathway for giving Medicare beneficiaries earlier access to certain medical devices bears similarities to previous programs that did not advance coverage significantly, and thus may only benefit certain manufacturers, say attorneys at King & Spalding.

  • How Cos. Can Avoid Infant Product False Advertising Suits

    Author Photo

    As lawsuits proliferate over products marketed for infant use and sold at a premium that are identical to cheaper general-use products, manufacturers should review related product lines, and scrutinize contextual cues that may contribute to the overall message received by consumers, say attorneys at Chamberlain Hrdlicka.

  • 9th Circ. Ruling Raises Bar For Arbitration Pacts Via Email

    Author Photo

    The Ninth Circuit's recent holding in Rickes v. Thermo Fisher that the mere delivery of an email doesn't establish an employee's assent to the arbitration agreement underscores that rollout processes should both give employees notice of the agreement and create evidence of their assent, say attorneys at Sullivan & Cromwell.

  • A Road Map To Modernizing Clinical Lab Regulations

    Author Photo

    The Centers for Medicare & Medicaid Services' recent request for comments on potential changes to the Clinical Laboratory Improvement Amendments provides an early indication of where CLIA is headed, and the operational, compliance, reimbursement and enforcement issues those changes will create, says Jose Vela at Clark Hill.

  • Where AI Patent Risk Begins And How Records Can Help

    Author Photo

    The Federal Circuit's recent decision in Dental Monitoring v. Align highlights the importance of documenting how artificial intelligence-assisted inventions work, and how humans contributed, as such records can support inventorship, written description, eligibility and definiteness requirements, say attorneys at Sterne Kessler.

  • 2nd Circ. Tylenol MDL Ruling Clarifies Court Gatekeeper Role

    Author Photo

    The Second Circuit’s recent decision in multidistrict litigation over alleged links between Tylenol and developmental disorders, holding that the trial court improperly excluded expert witnesses, preserves meaningful judicial gatekeeping while making clear that judges may not resolve legitimate scientific disputes themselves, say attorneys at Lowenstein Sandler.

  • Series

    Law School's Missed Lessons: Cultivating Good Judgment

    Author Photo

    Law schools generally overlook the role that solid judgment skills play in real-world practice, but attorneys can bridge the gap by strengthening their abilities to assess a case’s strengths and weaknesses, develop and execute effective strategies, and provide clear recommendations to clients, says Manny Caixeiro at Venable.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.